Clinical Trials Browser

Phase 1/2 × Prostatic Neoplasms × Erlotinib Hydrochloride × Clear all

NCT00996502 2019-03-27

Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer

Phase 1/2 Terminated

4 enrolled 2 charts

Prostatic Neoplasms